)
)
Moderna Investor Relations Material
Latest events
Q3 2024
Latest reports from Moderna Inc
Pioneering mRNA technology
Moderna was founded on the notion that messenger RNA (mRNA), the molecule sending genetic information from DNA to the cell’s protein factory, could be re-engineered into a versatile set of drugs and vaccines.
With these instructions from the mRNA, our cells could be taught to make whatever our bodies need to treat or prevent disease - virus-slaying antibodies, metabolism-improving enzymes, or heart-caring treats.
Wide range of treatments and vaccines
Founded in September 2010 as “ModeRNA Therapeutics,” named from the combined terms “modified” and “RNA,” the company today has produced 44 different treatments and vaccine candidates, of which 21 have entered clinical trials.
In their pipeline are, among others, vaccines and treatments for influenza, HIV, COVID-19, cancer, and coronary heart disease (CHD). With a market cap of $57 billion, many undoubtedly believe in Moderna's future products.
Key slides for Moderna Inc
Q3 2024
Q3 2024
Latest articles
)
An in-depth look at the largest aftermarket auto parts retailer in the U.S., its philosophy, and masterful capital allocation.
)
Gautam Baid's journey of compounding wisdom, investing simplicity, and lifelong learning – insights to transform your financial and personal growth.
)